Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Antioxidant showed no clear difference in severe adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether anti‐VEGF changes ocular adverse events compared with control (very low certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).
It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).
It is very uncertain whether transjugular intrahepatic portosystemic shunts changes serious adverse events compared with conventional treatment (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).